Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYP-2090PTSA in KRAS-mutated advanced solid tumors
NCT06243354Phase 2Recruiting
- Sponsor
- Sichuan Huiyu Pharmaceuticals
- Start
- Feb 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HY-0002a in solid tumor, sponsored by Sichuan Huiyu Pharmaceuticals. Primary endpoints: Recommended Phase 2 Dose at 2 years and Dose Limiting Toxicities at 24 days. Started Feb 2024; status: recruiting.
02
Drugs
HY-0002a
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06243354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06243354.